Five-year outcomes of patients supported with HeartMate 3: A single-centre experience
Schmitto J.D. Mariani S. Li T. Dogan G. Hanke J.S. Bara C. Pya Y. Zimpfer D. Krabatsch T. Garbade J. Rao V. Morshuis M. Beyersdorf F. Marasco S. Netuka I. Bauersachs J. Haverich A.
1 June 2021European Association for Cardio-Thoracic Surgery
European Journal of Cardio-thoracic Surgery
2021#59Issue 61155 - 1163 pp.
OBJECTIVES: The HeartMate 3 left ventricular assist device was first implanted in 2014 and received the Conformité Européenne mark in 2015. Since then, several trials demonstrated its high haemocompatibility associated with good survival and low adverse events rates. Herein, we report our institutional experience with patients supported with HeartMate 3 for 5 years. METHODS: This prospective cohort study included patients receiving a HeartMate 3 implantation in 2014 as part of the HeartMate 3 Conformité Européenne Mark clinical trial. Patients had follow-up visits every 3 months while on left ventricular assist device support, and all patients completed the 5-year follow-up. The primary end point was survival at 5 years. Secondary end points included adverse events, health status and quality of life. RESULTS: Eight patients (men: 75%) aged 59 years (min-max: 52-66 years) were enrolled. At 5 years, survival was 100%. Patients remained on support for a median time of 1825 days (min-max: 101-1825 days); 2 patients successfully received cardiac transplants. No right heart failure, haemolysis, pump thrombosis, pump malfunction or neurological events occurred in any patients. A driveline infection was observed in 6 patients (0.25 events/patient-year). Compared to baseline, a significant improvement in quality of life and in New York Heart Association functional class was noted after the implant and for the whole follow-up time. A slight decline in kidney function and in the 6-min walk test results occurred after 3 years. CONCLUSIONS: This study reports the longest single-centre follow-up of the HeartMate 3, showing excellent haemocompatibility over time with high survival and low complication rates at 5 years.
Heart failure , HeartMate 3 , Left ventricular assist device , Mechanical circulatory support
Text of the article Перейти на текст статьи
Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
National Research Cardiac Surgery Center, Nur-Sultan, Kazakhstan
Division of Cardiac Surgery, Department of Surgery, Medical University Vienna, Vienna, Austria
Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany
University Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany
Department of Cardiovascular Surgery, Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, ON, Canada
Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center, Bad Oeynhausen, Germany
Department of Cardiovascular Surgery, University Heart Center Freiburg, and Medical Faculty of the Albert-Ludwigs-University Freiburg, Freiburg, Germany
Department of Cardiothoracic Surgery and Transplantation, Alfred Hospital and Monash University, Melbourne, Australia
Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
Department of Cardiothoracic
National Research Cardiac Surgery Center
Division of Cardiac Surgery
Department of Cardiothoracic and Vascular Surgery
University Department of Cardiac Surgery
Department of Cardiovascular Surgery
Clinic for Thoracic and Cardiovascular Surgery
Department of Cardiovascular Surgery
Department of Cardiothoracic Surgery and Transplantation
Department of Cardiovascular Surgery
Department of Cardiology and Angiology
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026